Efficacy of remote physiological monitoring-guided care for chronic heart failure: an updated meta-analysis.


Journal

Heart failure reviews
ISSN: 1573-7322
Titre abrégé: Heart Fail Rev
Pays: United States
ID NLM: 9612481

Informations de publication

Date de publication:
09 2022
Historique:
accepted: 24 09 2021
pubmed: 6 10 2021
medline: 23 8 2022
entrez: 5 10 2021
Statut: ppublish

Résumé

Previous studies have reported contradictory findings on the utility of remote physiological monitoring (RPM)-guided management of patients with chronic heart failure (HF). Multiple databases were searched for studies that evaluated the clinical efficacy of RPM-guided management versus standard of care (SOC) for HF patients. The primary outcome was HF-related hospitalization (HFH). The secondary outcomes were all-cause mortality, cardiovascular-related (CV) mortality, and emergency department (ED) visits. Pooled relative risk (RR) and corresponding 95% confidence intervals (CIs) were calculated and combined using a random-effects model. A total of 16 randomized controlled trials, including 8679 HF patients (4574 managed with RPM-guided therapy vs. 4105 managed with SOC), were included in the final analysis. The average follow-up period was 15.2 months. There was no significant difference in HFH rate between the two groups (RR: 0.94; 95% CI: 0.84-1.07; P = 0.36). Similarly, there were no significant differences in CV mortality (RR 0.86, 95% CI 0.73-1.02, P = 0.08) or in ED visits (RR 0.80, 95% CI 0.59-1.08, P = 0.14). However, RPM-guided therapy was associated with a borderline statistically significant reduction in all-cause mortality (RR: 0.88; 95% CI: 0.78-1.00; P = 0.05). Subgroup analysis based on the strategy of RPM showed that both hemodynamic and arrhythmia telemonitoring-guided management can reduce the risk of HFH (RR: 0.79; 95% CI: 0.64-0.97; P = 0.02) and (RR: 0.79; 95% CI: 0.67-0.94; P = 0.008) respectively. Our study demonstrated that RPM-guided diuretic therapy of HF patients did not reduce the risk of HFH but can improve survival. Hemodynamic and arrhythmia telemonitoring-guided management could reduce the risk of HF-related hospitalizations.

Identifiants

pubmed: 34609716
doi: 10.1007/s10741-021-10176-9
pii: 10.1007/s10741-021-10176-9
doi:

Types de publication

Journal Article Meta-Analysis Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1627-1637

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Zile MR, Bennett TD, St John Sutton M et al (2008) Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation 118:1433–1441
Ambrosy AP, Fonarow GC, Butler J et al (2014) The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 63:1123–1133
doi: 10.1016/j.jacc.2013.11.053
Lainscak M, Cleland JG, Lenzen MJ et al (2007) Recall of lifestyle advice in patients recently hospitalised with heart failure: a EuroHeart Failure Survey analysis. Eur J Heart Fail 9:1095–1103
doi: 10.1016/j.ejheart.2007.08.001
Ali O, Hajduczok AG, Boehmer JP (2020) Remote physiologic monitoring for heart failure. Curr Cardiol Rep 22:68
doi: 10.1007/s11886-020-01309-x
Abraham WT, Adamson PB, Bourge RC et al (2011) Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 377:658–666
doi: 10.1016/S0140-6736(11)60101-3
Bourge RC, Abraham WT, Adamson PB et al (2008) Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. J Am Coll Cardiol 51:1073–1079
doi: 10.1016/j.jacc.2007.10.061
Hindricks G, Taborsky M, Glikson M et al (2014) Implant-based multiparameter telemonitoring of patients with heart failure (IN-TIME): a randomised controlled trial. Lancet 384:583–590
doi: 10.1016/S0140-6736(14)61176-4
Al-Khatib SM, Piccini JP, Knight D, Stewart M, Clapp-Channing N, Sanders GD (2010) Remote monitoring of implantable cardioverter defibrillators versus quarterly device interrogations in clinic: results from a randomized pilot clinical trial. J Cardiovasc Electrophysiol 21:545–550
doi: 10.1111/j.1540-8167.2009.01659.x
van Veldhuisen DJ, Braunschweig F, Conraads V et al (2011) Intrathoracic impedance monitoring, audible patient alerts, and outcome in patients with heart failure. Circulation 124:1719–1726
doi: 10.1161/CIRCULATIONAHA.111.043042
Landolina M, Perego GB, Lunati M et al (2012) Remote monitoring reduces healthcare use and improves quality of care in heart failure patients with implantable defibrillators: the evolution of management strategies of heart failure patients with implantable defibrillators (EVOLVO) study. Circulation 125:2985–2992
doi: 10.1161/CIRCULATIONAHA.111.088971
Alotaibi S, Hernandez-Montfort J, Ali OE, El-Chilali K, Perez BA (2020) Remote monitoring of implantable cardiac devices in heart failure patients: a systematic review and meta-analysis of randomized controlled trials. Heart Fail Rev 25:469–479
doi: 10.1007/s10741-020-09923-1
Böhm M, Drexler H, Oswald H et al (2016) Fluid status telemedicine alerts for heart failure: a randomized controlled trial. Eur Heart J 37:3154–3163
doi: 10.1093/eurheartj/ehw099
Tajstra M, Sokal A, Gadula-Gacek E et al (2020) Remote Supervision to Decrease Hospitalization Rate (RESULT) study in patients with implanted cardioverter-defibrillator. Europace 22:769–776
doi: 10.1093/europace/euaa072
Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700
Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses Bmj 327:557–560
pubmed: 12958120
Iyengar S, Greenhouse J (2009) Sensitivity analysis and diagnostics. Handbook of research synthesis and meta-analysis 417–433
Higgins PT, Altman DG, Gøtzsche PC et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 43:d5928
Adamson PB, Gold MR, Bennett T et al (2011) Continuous hemodynamic monitoring in patients with mild to moderate heart failure: results of The Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (REDUCEhf) trial. Congest Heart Fail 17:248–254
doi: 10.1111/j.1751-7133.2011.00247.x
Boriani G, Da Costa A, Quesada A et al (2017) Effects of remote monitoring on clinical outcomes and use of healthcare resources in heart failure patients with biventricular defibrillators: results of the MORE-CARE multicentre randomized controlled trial. Eur J Heart Fail 19:416–425
doi: 10.1002/ejhf.626
Domenichini G, Rahneva T, Diab IG et al (2016) The lung impedance monitoring in treatment of chronic heart failure (the LIMIT-CHF study). Europace 18:428–435
doi: 10.1093/europace/euv293
Hansen C, Loges C, Seidl K et al (2018) INvestigation on Routine Follow-up in CONgestive HearT FAilure Patients with Remotely Monitored Implanted Cardioverter Defibrillators SysTems (InContact). BMC Cardiovasc Disord 18:131
doi: 10.1186/s12872-018-0864-7
Lüthje L, Vollmann D, Seegers J, Sohns C, Hasenfuß G, Zabel M (2015) A randomized study of remote monitoring and fluid monitoring for the management of patients with implanted cardiac arrhythmia devices. Europace 17:1276–1281
doi: 10.1093/europace/euv039
Morgan JM, Kitt S, Gill J et al (2017) Remote management of heart failure using implantable electronic devices. Eur Heart J 38:2352–2360
doi: 10.1093/eurheartj/ehx227
Sardu C, Santamaria M, Rizzo MR et al (2016) Telemonitoring in heart failure patients treated by cardiac resynchronisation therapy with defibrillator (CRT-D): the TELECART Study. Int J Clin Pract 70:569–576
doi: 10.1111/ijcp.12823
Varma N, Epstein AE, Irimpen A, Schweikert R, Love C (2010) Efficacy and safety of automatic remote monitoring for implantable cardioverter-defibrillator follow-up: the Lumos-T Safely Reduces Routine Office Device Follow-up (TRUST) trial. Circulation 122:325–332
doi: 10.1161/CIRCULATIONAHA.110.937409
Abraham WT, Stevenson LW, Bourge RC, Lindenfeld JA, Bauman JG, Adamson PB (2016) Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. Lancet 387:453–461
doi: 10.1016/S0140-6736(15)00723-0
Angermann CE, Assmus B, Anker SD et al (2020) Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF). Eur J Heart Fail 22:1891–1901
doi: 10.1002/ejhf.1943
Adamson PB, Ginn G, Anker SD, Bourge RC, Abraham WT (2017) Remote haemodynamic-guided care for patients with chronic heart failure: a meta-analysis of completed trials. Eur J Heart Fail 19:426–433
doi: 10.1002/ejhf.638
Yu CM, Wang L, Chau E et al (2005) Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation 112:841–848
doi: 10.1161/CIRCULATIONAHA.104.492207
Hawkins NM, Virani SA, Sperrin M, Buchan IE, McMurray JJ, Krahn AD (2016) Predicting heart failure decompensation using cardiac implantable electronic devices: a review of practices and challenges. Eur J Heart Fail 18:977–986
doi: 10.1002/ejhf.458
Klersy C, De Silvestri A, Gabutti G et al (2011) Economic impact of remote patient monitoring: an integrated economic model derived from a meta-analysis of randomized controlled trials in heart failure. Eur J Heart Fail 13:450–459
doi: 10.1093/eurjhf/hfq232
Hudson LR, Hamar GB, Orr P et al (2005) Remote physiological monitoring: clinical, financial, and behavioral outcomes in a heart failure population. Dis Manag 8:372–381
doi: 10.1089/dis.2005.8.372
Shavelle DM, Desai AS, Abraham WT et al (2020) Lower rates of heart failure and all-cause hospitalizations during pulmonary artery pressure-guided therapy for ambulatory heart failure: one-year outcomes from the CardioMEMS post-approval study. Circ Heart Fail 13:e006863
Bui AL, Fonarow GC (2012) Home monitoring for heart failure management. J Am Coll Cardiol 59:97–104
doi: 10.1016/j.jacc.2011.09.044

Auteurs

Mohammed Mhanna (M)

Department of Internal Medicine, The University of Toledo, Toledo, OH, USA. Mohammed.Mhanna@utoledo.edu.

Azizullah Beran (A)

Department of Internal Medicine, The University of Toledo, Toledo, OH, USA.

Salik Nazir (S)

Department of Cardiovascular Medicine, University of Toledo, Toledo, OH, USA.

Ahmad Al-Abdouh (A)

Department of Internal Medicine, Saint Agnes Hospital, Baltimore, MD, USA.

Mahmoud Barbarawi (M)

Department of Cardiovascular Medicine, University of Connecticut, Farmington, CT, USA.

Omar Sajdeya (O)

Department of Internal Medicine, The University of Toledo, Toledo, OH, USA.

Omar Srour (O)

Department of Internal Medicine, The University of Toledo, Toledo, OH, USA.

Mohammad Altujjar (M)

Department of Internal Medicine, Promedica Toledo Hospital, Toledo, OH, USA.

Ronak B Patel (RB)

Department of Cardiovascular Medicine, Promedica Toledo Hospital, Toledo, OH, USA.

Ehab A Eltahawy (EA)

Department of Cardiovascular Medicine, University of Toledo, Toledo, OH, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH